Gilead Sciences News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

17.12.24	FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy For Treatment Of Small Cell Lung Cancer (RTTNews)
17.12.24	Gilead Inks Strategic Collaboration With Terray Therapeutics To Develop Small Molecule Therapies (RTTNews)
13.12.24	Gilead Sciences Says Seladelpar Gets Positive CHMP Opinion For Primary Biliary Cholangitis (RTTNews)
03.12.24	Gilead, Tubulis Partner To Develop ADC Candidate For Solid Tumor Target (RTTNews)
29.11.24	Gilead's Twice-Yearly Lenacapavir Reduces HIV Infection Risk (RTTNews)
17.11.24	Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management (RTTNews)
14.11.24	Gilead Prices $3.5 Bln Of Senior Unsecured Notes (RTTNews)
07.11.24	Gilead Sciences Inc. Q3 Profit Decreases, But Beats Estimates (RTTNews)
20.10.24	Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment (RTTNews)
08.10.24	Gilead Sciences : Phase 3 Data Shows 96% Reduction In HIV Infections With Lenacapavir (RTTNews)
02.10.24	Gilead Partners 6 Pharma Cos. To Provide Generic Lenacapavir In High-incidence Countries (RTTNews)
24.09.24	Gilead Recalls COVID-19 Drug Veklury For Injection (RTTNews)
12.09.24	Gilead: Lenacapavir Reduces HIV Infections By 96% In PURPOSE 2 Trial (RTTNews)
10.09.24	Gilead Sciences To Work With Genesis To Apply AI Platform To Discover, Advance Therapies (RTTNews)
18.08.24	Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out (RTTNews)
15.08.24	Gilead Sciences' Livdelzi Receives Accelerated FDA Approval For Primary Biliary Cholangitis (RTTNews)
11.08.24	Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray (RTTNews)
08.08.24	Gilead Sciences Q2 Profit Rises, Revises Full-year Guidance - Update (RTTNews)
08.08.24	Gilead Sciences Inc. Bottom Line Rises In Q2, But Misses Estimates (RTTNews)
29.07.24	Biotech Stocks Facing FDA Decision In August 2024 (RTTNews)
25.07.24	Gilead's New Data Reinforce Biktarvy As Long-Term HIV Treatment Option; Stock Up (RTTNews)
24.07.24	Gilead's Twice-yearly Injection Offers 100% Protection Against HIV In Women: Study (RTTNews)
24.07.24	Gilead Sciences Reports New Efficacy, Safety Results From Lenacapavir Trial For HIV Prevention (RTTNews)
23.07.24	Researchers Suggest That A Costly New HIV Drug By Gilead Could Cost As Little As $40 (RTTNews)
17.07.24	Gilead Sciences Chief Medical Officer Merdad Parsey To Resign (RTTNews)
05.06.24	Gilead Announces Long-term Safety And Efficacy Data For Seladelpar In Primary Biliary Cholangitis (RTTNews)
03.06.24	Kite's Yescarta Pilot Study Shows Toleration In Relapsed/Refractory Central Nervous System Lymphoma (RTTNews)
03.06.24	Kite Says Tecartus Shows Prolonged OS In Adults With Refractory B-cell Acute Lymphoblastic Leukemia (RTTNews)
31.05.24	Gilead : Phase 3 Study Of Trodelvy In Metastatic Urothelial Cancer Fails To Meet Primary Endpoint (RTTNews)
18.05.24	Gilead's Seladelpar Shows Major Liver Disease Progression Improvement, Itch Reduction In PBC Study (RTTNews)
26.04.24	Gilead Sciences Says FDA OK's Updated Label Of Biktarvy To Treat Pregnant People With HIV-1 (RTTNews)
25.04.24	Gilead Sciences Inc. Q1 Earnings Summary (RTTNews)
02.04.24	Nurix Therapeutics Says Gilead Sciences Extends Ongoing Strategic Collaboration By Addl. Two Years (RTTNews)
28.03.24	Gilead's SNDA For Vemlidy Gets FDA Approval To Treat Chronic HBV Infection In Pediatric Patients (RTTNews)
28.03.24	Gilead, Xilio Announce Exclusive License Agreement For Tumor-Activated IL-12 Program XTX301 (RTTNews)
22.03.24	Gilead Sciences Completes Acquisition Of CymaBay Therapeutics (RTTNews)
11.03.24	Gilead Sciences Announces Expiration Of HSR Waiting Period For CymaBay Tender Offer (RTTNews)
27.02.24	Gilead Sciences : FDA Expands Biktarvy Indication For HIV Treatment (RTTNews)
12.02.24	Gilead To Acquire CymaBay; To Enhance Revenue Growth Upon Approval Of Seladelpar (RTTNews)
06.02.24	Gilead Sciences Inc. Q4 Profit Decreases, misses estimates (RTTNews)
30.01.24	Gilead's Kite Receives FDA Approval For Yescarta Manufacturing Process Change (RTTNews)
30.01.24	Gilead Sciences Increases Stake In Arcus Biosciences To 33% (RTTNews)
22.12.23	FDA Approves Label Update For Kite's Yescarta CAR T-Cell Therapy To Include Overall Survival Data (RTTNews)
21.12.23	Hookipa Pharma Says Gilead Purchases Addl. 15 Mln Shares Of HOOKIPA For Total Stake Of About 19.4% (RTTNews)
19.12.23	Gilead Sciences, Compugen Ink Up To $848 Mln Deal For Pre-clinical Antibody Program (RTTNews)
04.12.23	IDEAYA To Evaluate IDE397 In Combination With Gilead's Trodelvy - Quick Facts (RTTNews)
20.11.23	HOOKIPA Pharma: HB-500 IND Application Gets FDA Clearance To Treat HIV (RTTNews)
15.11.23	Gilead's Kite, Arcellx Expand Partnership (RTTNews)
07.11.23	Gilead Sciences Inc. Q3 Profit Increases, beats estimates (RTTNews)
31.10.23	Gilead's Kite, Epic Bio To Develop New Therapies For Cancer (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Roche Hldg G	255.50	0.75 %	K V
Nestle	74.88	0.62 %	K V
CieFinRichemont	137.90	0.40 %	K V
Swiss Life Hldg	699.60	0.32 %	K V
Swisscom	504.50	0.30 %	K V
Sika	215.80	-0.37 %	K V
Givaudan	3’966.00	-0.40 %	K V
Lonza Grp	535.80	-0.41 %	K V
Geberit	514.60	-0.46 %	K V
ABB	49.07	-0.95 %	K V

mehr

30.12.24		Montagshandel in New York: Dow Jones fällt schlussendlich zurück
30.12.24		FTSE 100-Handel aktuell: FTSE 100 fällt zum Handelsende
30.12.24		Börse Zürich in Grün: SMI steigt schlussendlich
30.12.24		Schwacher Wochentag in Europa: STOXX 50 letztendlich im Minus
30.12.24		Börse Frankfurt: LUS-DAX schwächelt letztendlich
30.12.24		Zurückhaltung in Zürich: SLI fällt letztendlich zurück
30.12.24		Aufschläge in Zürich: SPI beendet den Handel im Plus

30.12.24

Montagshandel in New York: Dow Jones fällt schlussendlich zurück

30.12.24

FTSE 100-Handel aktuell: FTSE 100 fällt zum Handelsende

30.12.24

Börse Zürich in Grün: SMI steigt schlussendlich

30.12.24

Schwacher Wochentag in Europa: STOXX 50 letztendlich im Minus

30.12.24

Börse Frankfurt: LUS-DAX schwächelt letztendlich

30.12.24

Zurückhaltung in Zürich: SLI fällt letztendlich zurück